Primary Biliary Cholangitis

Target Audience

The educational design of this activity addresses the needs of gastroenterology and hepatology specialist physicians, nurse practitioners (NPs), and physician associates (PAs) who are involved in managing patients with primary biliary cholangitis (PBC).

Program Overview

PBC is a progressive autoimmune liver disease characterized by the destruction of intrahepatic bile ducts that, if left untreated, can lead to liver failure and, ultimately, the need for liver transplantation. This multimedia eHealth Source™ has been designed to support early identification of disease, as well as the timely implementation of effective therapy for PBC. Specific topic areas covered in this activity include guideline-directed diagnostic and prognostic measures, monitoring and treatment modification procedures, data for the use of newly US Food and Drug Administration–approved peroxisome proliferator–activated receptor (PPAR) agonists, and strategies for translating evolving evidence to practice. Clinical evidence will be augmented with video commentary from expert faculty and patients with PBC, providing invaluable insight on lived experiences and actionable recommendations for practicing clinicians.

Educational Objectives

After completing this activity, the participant should be better able to:

1. Describe the pathogenesis, progression, and consequent disease manifestations of PBC, including signs, symptoms, and associated comorbidities in diverse patient populations
2. Utilize evidence-based diagnostic criteria and noninvasive assessment strategies to identify patients with PBC early in the disease course
3. Outline data on the safety, efficacy, and placement of novel PPAR agonist therapies for the treatment of PBC
4. Adopt timely monitoring schedules to assess disease symptoms, treatment response, and need to escalate pharmacotherapy
5. Construct management plans informed by patient disease profiles, comorbidities, therapeutic responses, and the psychosocial aspects of PBC

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal.

The American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) Recognition Statement

• Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
• For ABIM MOC points, your information will be shared with the ABIM through Integritas’ Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
• By sharing your Diplomate Board ID # and DOB, you are giving Integritas Communications permission to use this information/data to report your participation to these Boards via the PARS.

Integritas Contact Information

For more information about the approval (ACCME credit) of this program, please contact Integritas at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score at least 75% on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas and Global Education Group adhere to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty has the following relevant financial relationships with ineligible companies:

Nancy S. Reau, MD: Consulting Fees: Arbutus Biopharma, Gilead Sciences, Inc., Salix Pharmaceuticals, Inc., Vir Biotechnology, Inc.; Contracted Research: AbbVie, Gilead Sciences, Inc.

The planners and managers at Integritas Communications and Global Education Group have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas and Global do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.